Chemours
CC
$21.44
-3.73%
The Chemours Company is a global provider of performance chemicals, operating in the Specialty Chemicals industry with core segments including Titanium Technologies (TiO2 pigment), Thermal & Specialized Solutions, and Advanced Performance Materials. It is a significant player in the chemicals sector, particularly as a major producer of TiO2 pigment, a critical white pigment used across paints, coatings, plastics, and other industrial applications. The current investor narrative is heavily influenced by geopolitical tensions impacting global commodity markets, as seen in recent news highlighting supply shocks and price pressures for chemicals, while the company's continued dividend payments signal a focus on shareholder returns amidst a volatile operating environment.…
CC
Chemours
$21.44
Related headlines
Investment Opinion: Should I buy CC Today?
Rating: Hold. The core thesis is that while the explosive momentum and low sales multiple are compelling, the extreme financial leverage and current unprofitability create an asymmetric risk profile that outweighs the potential near-term upside, making the stock suitable only for highly risk-tolerant investors.
The Hold rating is supported by conflicting data points: the bullish forward P/E of 11.6x (based on estimated EPS of $2.74) suggests undervaluation if profits materialize, and the extremely low PS ratio of 0.31x offers a margin of safety on sales. However, these are counterbalanced by the severe bearish metrics of a debt-to-equity ratio of 18.34, a trailing ROE of -154.4%, and a net margin of -6.65%. The stock's 4.4% dividend yield provides some income support, but the negative payout ratio indicates it is not currently covered by earnings.
The two biggest risks invalidating a more positive view are 1) the company failing to achieve the analyst-forecasted EPS of $2.74, and 2) a deterioration in credit markets exacerbating its high debt burden. This Hold would upgrade to a Buy if the company demonstrates sustained quarterly profitability (positive net income) and reduces its debt-to-equity ratio meaningfully. It would downgrade to a Sell if the stock breaks below key technical support (e.g., the $17 level from March 2026) on high volume, signaling the momentum trend has broken, or if forward EPS estimates are revised downward significantly. On valuation, the stock appears fairly valued for the extreme risk it presents; the low sales multiple discounts the financial distress, while the forward earnings multiple prices in a successful but uncertain recovery.
Sign up to view all
CC 12-Month Price Forecast
The outlook for Chemours is bifurcated and highly contingent on execution. The base case (50% probability) of range-bound consolidation is most likely, as the market digests the massive rally and waits for proof of the forecasted profit recovery. The bullish scenario depends on flawless execution in a favorable commodity environment, while the bearish scenario is a real threat given the company's leveraged balance sheet and history of value destruction. The stance is neutral due to the offsetting forces of powerful momentum and profound fundamental risk. We would upgrade to bullish on confirmation of sustained profitability and debt reduction, and downgrade to bearish on a breakdown of the uptrend or a material earnings miss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Chemours's 12-month outlook, with a consensus price target around $27.87 and implied upside of +30.0% versus the current price.
Average Target
$27.87
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$17 - $28
Analyst target range
Analyst coverage for Chemours is limited, with only 7 analysts providing estimates, which is typical for a mid-cap, cyclical industrial company and can lead to higher volatility and less efficient price discovery. The available data focuses on forward estimates, with an average EPS forecast of $2.74 for the coming period, implying a significant expected turnaround from current losses and supporting the forward P/E of 11.6x. A full target price range, consensus recommendation, and implied upside/downside from the current price are not provided in the dataset, which limits the ability to gauge overall sentiment, conviction levels, and the specific bullish or bearish assumptions embedded in analyst models.
Bulls vs Bears: CC Investment Factors
The investment debate for Chemours is a classic battle between a powerful technical momentum/expectations-driven rally and severe fundamental financial risks. The bull side currently has stronger short-term evidence, driven by an explosive 114% price surge and analyst expectations of a dramatic EPS recovery to $2.74. However, the bear case is grounded in more durable, structural concerns: an unsustainable debt load (D/E of 18.34) and current unprofitability (net margin -6.65%). The single most important tension is whether the company can successfully navigate its leveraged balance sheet to deliver the analyst-forecasted profit recovery, or if the debt burden will cripple the turnaround. The outcome of this tension—profitability vs. solvency—will ultimately determine the stock's direction.
Bullish
- Parabolic Price Momentum: The stock has surged 113.91% over the past year and 28.12% in the last month, dramatically outperforming the S&P 500. This powerful technical uptrend, trading just $0.04 below its 52-week high, signals strong market conviction in a turnaround story.
- Analyst Expects Sharp Profit Recovery: Analysts forecast a significant EPS rebound to $2.74, implying a forward P/E of 11.6x. This expectation of a return to profitability from a trailing EPS of -$0.22 is the core bullish narrative, suggesting the current losses are cyclical rather than structural.
- Extremely Low Sales-Based Valuation: The stock trades at a trailing Price-to-Sales ratio of just 0.31x and an EV/Sales of 1.27x. These are distressed-level multiples that could offer substantial upside if the company's profitability recovers as analysts expect, providing a margin of safety on the top line.
- Dividend Signals Cash Flow Stability: Despite current losses, the company maintains a dividend with a 4.4% yield, as evidenced by recent news. This signals management's confidence in generating sufficient cash flow to support shareholder returns, a positive sign amidst operational volatility.
Bearish
- Extreme Financial Leverage: The company carries a dangerously high debt-to-equity ratio of 18.34. This massive leverage amplifies risk, making the equity highly sensitive to operational setbacks and interest rate fluctuations, and constrains financial flexibility.
- Current Unprofitability and Weak Margins: The company is unprofitable with a trailing net margin of -6.65% and a thin gross margin of 15.53%. The operating margin is nearly breakeven at -0.09%, indicating fundamental challenges in its commodity-chemical business model and significant cost pressures.
- Technically Overextended Near Highs: Trading at $26.61, the stock is at the very top of its 52-week range ($9.13-$26.65) after a parabolic 113.91% run. This extreme momentum, coupled with a high beta of 1.4, creates high vulnerability to a sharp profit-taking pullback or trend reversal.
- High Short Interest Indicates Skepticism: A short ratio of 2.85 indicates significant bearish bets against the stock. This reflects market skepticism about the sustainability of the recent rally and the company's ability to execute the expected earnings turnaround, posing a headwind to further gains.
CC Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 113.91% price increase over the past year. With a current price of $26.61, it is trading at the very top of its 52-week range, just $0.04 below the 52-week high of $26.65, indicating extreme momentum but also raising concerns about potential overextension and vulnerability to a sharp pullback. Recent momentum has been exceptionally strong, with the stock surging 28.12% over the past month and 68.95% over the past three months, significantly outpacing the S&P 500's gains of 8.7% and 3.59% respectively; this acceleration suggests the bullish trend is intensifying, though such parabolic moves often precede periods of consolidation. Key technical levels are clear, with immediate resistance at the 52-week high of $26.65 and support at the 52-week low of $9.13; a confirmed breakout above resistance could signal a continuation of the rally, while a failure here may trigger profit-taking. The stock's beta of 1.403 indicates it is approximately 40% more volatile than the broader market, which is critical for risk management as it implies larger swings in both directions.
Beta
1.46
1.46x market volatility
Max Drawdown
-40.2%
Largest decline past year
52-Week Range
$9-$29
Price range past year
Annual Return
+103.4%
Cumulative gain past year
| Period | CC Return | S&P 500 |
|---|---|---|
| 1m | -9.6% | +5.5% |
| 3m | +25.8% | +7.7% |
| 6m | +94.0% | +12.7% |
| 1y | +103.4% | +27.4% |
| ytd | +75.0% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CC Fundamental Analysis
Revenue trajectory analysis is constrained as specific quarterly revenue and growth rate figures are not available in the provided data, limiting insight into the top-line trend and segment performance. The company is currently unprofitable on a net income basis, with a trailing EPS of -$0.22 and a net margin of -6.65%, though the forward P/E of 11.6x suggests analysts expect a return to profitability. Gross margin stands at a relatively thin 15.53%, and the operating margin is nearly breakeven at -0.09%, indicating significant cost pressures or pricing challenges within its commodity-chemical business model. The balance sheet shows a very high degree of financial leverage with a debt-to-equity ratio of 18.34, which poses substantial risk, though this is partially offset by adequate short-term liquidity evidenced by a current ratio of 1.78. Key profitability metrics like Return on Assets (2.49%) and Return on Equity (-154.4%) paint a mixed picture of asset efficiency and significant shareholder value destruction on a trailing basis, underscoring the fundamental challenges the company faces.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CC Overvalued?
Given the negative trailing Net Income (EPS of -$0.22), the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 0.31x and an Enterprise Value-to-Sales (EV/Sales) of 1.27x, which are low multiples typically associated with low-margin, cyclical, or distressed businesses. Peer comparison data for the industry is not available in the provided dataset, preventing a quantitative assessment of whether this low multiple represents a discount or is in line with sector norms for specialty chemical companies. Historical context for the stock's own valuation multiples is also unavailable, making it impossible to determine if the current PS ratio is near the top or bottom of its historical range, which would help gauge if the market is pricing in pessimistic or improving expectations.
PE
-4.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe, centered on an extreme debt burden and weak profitability. The debt-to-equity ratio of 18.34 is alarmingly high, making the company vulnerable to rising interest rates and leaving little room for error. Current operations are unprofitable with a net margin of -6.65% and a wafer-thin operating margin of -0.09%, indicating the core business struggles to cover its costs. The company's reliance on a cyclical recovery in TiO2 pigment prices, as hinted by recent geopolitical commodity news, creates earnings volatility, and its dividend payout (4.4% yield) amidst losses could pressure cash flow if not supported by operational improvement.
Market & Competitive Risks are elevated due to valuation and sentiment shifts. The stock's parabolic 114% year-to-date run to its 52-week high leaves it technically overextended and vulnerable to a sharp mean reversion, especially given its high beta of 1.4, which implies 40% greater volatility than the market. Trading at a forward P/E of 11.6x hinges entirely on achieving forecasted EPS of $2.74; any disappointment could trigger multiple compression. As a commodity chemical producer, it faces intense global competition and pricing pressure, and its fortunes are tightly linked to industrial and construction cycles, making it highly macro-sensitive.
The Worst-Case Scenario involves a failure of the earnings turnaround coinciding with a broader market downturn. In this scenario, missed EPS targets lead to analyst downgrades, the high debt burden becomes a liquidity crisis as refinancing costs soar, and the dividend is cut, shattering investor confidence. The stock could rapidly unwind its gains, retracing toward its 52-week low of $9.13. From the current price of $26.61, this represents a catastrophic downside of approximately -66%. A more realistic severe bear case, considering the recent low around $11 in late 2025, suggests a potential drawdown of -50% to -60% is plausible if the bullish narrative completely unravels.
FAQ
The key risks, in order of severity, are: 1) Financial Risk: An extreme debt-to-equity ratio of 18.34 threatens solvency in a downturn and limits strategic flexibility. 2) Execution Risk: The company must deliver a dramatic turnaround to achieve the analyst-forecasted EPS of $2.74 from a current loss; any stumble could crater the stock. 3) Macro/Cyclical Risk: As a commodity chemical producer, CC's fortunes are tied to industrial and construction cycles, making revenues and margins highly volatile. 4) Technical Risk: After a 114% surge to its 52-week high, the stock is vulnerable to a sharp momentum reversal, exacerbated by its high beta of 1.4 and significant short interest (short ratio 2.85).
Our 12-month forecast outlines three scenarios with associated probabilities. The Base Case (50% probability) sees the stock consolidating in a $22-$28 range as the company makes uneven progress toward its EPS target of $2.74. The Bull Case (25% probability) projects a breakout to $32-$38 on successful execution and debt reduction. The Bear Case (25% probability) warns of a collapse back toward $9-$15 if the turnaround fails and leverage concerns escalate. The most likely outcome is the Base Case, as the market awaits concrete proof that the company can transition from its current loss-making state to sustained profitability while managing its massive debt load.
CC's valuation presents a paradox. On a sales basis, it appears deeply undervalued with a Price-to-Sales ratio of 0.31x, typical of distressed or deeply cyclical companies. On a forward earnings basis, assuming analysts are correct, it looks reasonably valued with a forward P/E of 11.6x. The market is essentially pricing in a successful turnaround but assigning a low multiple due to the high financial risk (debt) and operational risk (cyclicality). Therefore, it is fairly valued for the extreme binary outcome it represents. It is not cheap given its balance sheet, nor is it expensive if the profit recovery materializes as forecasted.
CC is a high-risk, high-potential-reward stock that may be suitable only for a specific type of investor. For aggressive traders or deep-value investors comfortable with extreme volatility and leverage, the low PS ratio of 0.31x and analyst expectation of a sharp EPS rebound to $2.74 present a compelling narrative. However, for most investors, it is not a 'good buy' due to the severe fundamental risks, including a debt-to-equity ratio of 18.34 and current unprofitability (net margin -6.65%). It could be a good buy for a speculative portion of a portfolio if purchased on a significant pullback, but the current price near 52-week highs after a 114% run offers a poor risk/reward setup.
CC is primarily suitable for medium-term tactical investing (6-18 months) rather than long-term buy-and-hold. Its high beta of 1.4 and cyclical nature make it too volatile for stable long-term compounding, and its dividend, while yielding 4.4%, is not currently covered by earnings. The investment thesis is centered on a specific turnaround and cycle recovery narrative expected to play out over the next few quarters. Short-term trading is also extremely risky due to the stock's parabolic move and high short interest, which can cause violent swings. The minimum suggested holding period aligns with the cycle, requiring patience to see through at least 2-3 earnings reports to validate the recovery story.